CND Life Sciences has opened a dedicated Innovation Laboratory in Scottsdale, Ariz., to expand assay development and biomarker research for neurodegenerative diseases, operating separately from its CLIA-certified clinical lab.
The University of Reading has developed the TRIPLEcheck assay to personalize antiplatelet therapy by assessing platelet reactivity, with a 400-patient clinical trial underway.
The FDA has cleared Aptitude’s next-generation Metrix COVID Test, which the company says offers 3-fold higher sensitivity and 30% faster results compared to its EUA version.
The College of American Pathologists has updated 14 Cancer Protocols, mandating the Breast Phyllodes Tumor protocol for accreditation and revising breast biomarker and GIST molecular testing criteria, according to CAP.
A nine-lab network evaluated four Bundibugyo virus PCR assays from two manufacturers in two weeks during the 2026 outbreak, establishing new reference standards, according to a study in The Lancet Infectious Diseases.
General practitioner requests for AMH fertility tests rose more than 13-fold from 2011 to 2021, despite research showing these tests cannot predict natural conception, according to a Flinders University study of 1.4 million health records.
A Vanderbilt study finds that standard genetic tests for lamotrigine reaction risk omit HLA-A*32:01, a marker linked to severe DRESS, raising concerns about current pharmacogenomic panel effectiveness.
A large trial finds that the rapid 0/1-hour cardiac troponin testing pathway is as safe as standard methods but does not reduce emergency department length of stay or increase direct discharge rates.
A Columbia University study finds that combining plasma p-tau217 blood tests with APOE4 genotyping can predict Alzheimer’s symptom onset within three to four years in high-risk, asymptomatic individuals.
A University of Exeter study finds that adding a genetic risk score to MODY testing can identify hidden type 1 diabetes in 16% of patients with negative genetic results, supporting updated NHS diagnostic protocols.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.